Author

S. S. Patil

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

A. Duensing· 2 shared D. M. Lee· 2 shared J. L. Rausch· 2 shared A. A. Ali· 1 shared A. A. Amir· 1 shared A. Agha· 1 shared A. Kaczorowski· 1 shared A. Sun· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Duensing

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeting the translational machinery in gastrointestinal stromal tumors (GIST) - a new therapeutic vulnerability

D. M. Lee, A. Sun, S. S. Patil, L. Liu, A. V. Rao, P. T. Trent, A. A. Amir, C. Liu, J. L. Rausch, L. D. Presutti, A. Kaczorowski, F. Schneider, N. Amankulor, M. Shuda, A. Duensing

This study shows that homoharringtonine (HHT) effectively inhibits KIT-dependent GIST growth by reducing protein synthesis, even in imatinib-resistant models.

bioRxiv · Sep 1, 2021Cancer Biology

Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells

J. L. Rausch, A. A. Ali, D. M. Lee, Y. K. Gebreyohannes, K. R. Mehalek, A. Agha, S. S. Patil, Y. Tolstov, J. Wellens, H. S. Dhillon, K. R. Makielski, M. Debiec-Rychter, P. Schoeffski, A. Wozniak, A. Duensing

This study evaluates second-generation proteasome inhibitors and ubiquitination regulators for their efficacy against imatinib-resistant GIST cells, finding that 20S proteasome inhibitors are effective while others show limited activity.

bioRxiv · Jan 9, 2020Cancer Biology